Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
INM 
InMed Pharmaceuticals Inc (INM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/04/2025: INM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -58.28% | Avg. Invested days 15 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 02/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.51M USD | Price to earnings Ratio - | 1Y Target Price 20 |
Price to earnings Ratio - | 1Y Target Price 20 | ||
Volume (30-day avg) 947456 | Beta 0.68 | 52 Weeks Range 1.99 - 9.38 | Updated Date 04/1/2025 |
52 Weeks Range 1.99 - 9.38 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -12.42 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -163.77% | Operating Margin (TTM) -198.46% |
Management Effectiveness
Return on Assets (TTM) -40.86% | Return on Equity (TTM) -83.5% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 40483 | Price to Sales(TTM) 0.52 |
Enterprise Value 40483 | Price to Sales(TTM) 0.52 | ||
Enterprise Value to Revenue 0.01 | Enterprise Value to EBITDA 1 | Shares Outstanding 1207190 | Shares Floating 1122091 |
Shares Outstanding 1207190 | Shares Floating 1122091 | ||
Percent Insiders 0.34 | Percent Institutions 13.7 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
InMed Pharmaceuticals Inc
Company Overview
History and Background
InMed Pharmaceuticals Inc. is a biopharmaceutical company specializing in the research and development of cannabinoid-based therapeutics. Founded in 2010, it has focused on developing novel therapies for diseases with high unmet medical needs.
Core Business Areas
- Drug Development: InMed develops cannabinoid-based drug candidates for various diseases, focusing on rare and orphan conditions.
- API Manufacturing: InMed produces pharmaceutical-grade cannabinoids.
Leadership and Structure
The leadership team consists of executives with experience in pharmaceuticals and biotechnology. The organizational structure is typical of a small biotech company with research, development, and administrative functions.
Top Products and Market Share
Key Offerings
- INM-755 (Topical Cannabinoid Cream): A cannabinoid cream for epidermolysis bullosa (EB). Market share is currently zero as it is still in clinical development. Competitors include companies developing therapies for EB such as Krystal Biotech (KRYS) and Abeona Therapeutics (ABEO).
- INM-901 (Systemic Cannabinoid): A cannabinoid therapeutic for ocular diseases, specifically glaucoma. Market share is currently zero as it is still in clinical development. Competitors include pharmaceutical companies with glaucoma treatments, such as Allergan (ABBV) and Novartis (NVS).
Market Dynamics
Industry Overview
The pharmaceutical industry is driven by innovation and regulatory approvals. The cannabinoid therapeutics market is growing, but faces regulatory hurdles and competition from established pharmaceutical companies.
Positioning
InMed is a smaller player in the cannabinoid therapeutics market, focusing on niche indications and leveraging its expertise in cannabinoid drug development. They are striving for orphan drug designation and early market entry.
Total Addressable Market (TAM)
The TAM for cannabinoid-based pharmaceuticals is estimated to reach billions of dollars by 2030. InMed targets specific rare disease indications with significant unmet needs, representing a subset of this TAM. Positioning depends on clinical trial success.
Upturn SWOT Analysis
Strengths
- Proprietary cannabinoid drug development platform
- Focus on rare and orphan diseases
- Strong intellectual property portfolio
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- Small market capitalization
Opportunities
- Potential for orphan drug designation
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
Threats
- Regulatory hurdles for cannabinoid-based drugs
- Competition from established pharmaceutical companies
- Clinical trial failures
Competitors and Market Share
Key Competitors
- GWPH
- KRYS
- ABBV
Competitive Landscape
InMed faces competition from established pharmaceutical companies with greater resources and regulatory expertise. Its competitive advantage lies in its focus on novel cannabinoid-based therapeutics and orphan drug designation.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by preclinical and clinical development progress.
Future Projections: Future growth is dependent on successful clinical trials and regulatory approvals of its drug candidates. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing clinical trials for INM-755 and INM-901.
Summary
InMed Pharmaceuticals is a development stage biotech focused on cannabinoids with strong IP. Its success depends on clinical trials and navigating regulations, while managing limited resources. The company targets orphan diseases creating both opportunities and risks. Approval of a product would significantly improve InMed's prospects, while clinical trial failures could threaten its viability.
Similar Companies
CRBP
Corbus Pharmaceuticals Holding
CRBP
Corbus Pharmaceuticals Holding
Sources and Disclaimers
Data Sources:
- Company Filings
- Press Releases
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About InMed Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Vancouver, BC, Canada | ||
IPO Launch date 2020-11-12 | President, CEO & Director Mr. Eric A. Adams B.S. Chem., M.I.B. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 13 | Website https://www.inmedpharma.com |
Full time employees 13 | Website https://www.inmedpharma.com | ||
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. It operates through two segments: InMed Pharma and BayMedica Commercial. The InMed Pharma segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, which is a small molecule compound acting as a selective dual CB1 /CB2 agonist; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.